Author(s): Fischer R, Vasilev N, Twyman RM, Schillberg S
Abstract Share this page
Abstract Plants can be used to produce a diverse repertoire of complex small-molecule compounds and recombinant proteins that are valuable as industrial and pharmaceutical products. But as we move from proof-of-principle experiments and begin to consider the realistic prospects of commercial production, the focus must shift from the achievement of target molecule production and move towards quality, purity and yield aspects that determine commercial feasibility. This review describes some of the recent advances that have been implemented to improve the development of integrated production processes for high-value molecules expressed in plants, including the introduction of novel procedures to increase the likelihood of regulatory acceptance. Copyright © 2015 Elsevier Ltd. All rights reserved.
This article was published in Curr Opin Biotechnol
and referenced in Biochemistry & Pharmacology: Open Access